Document Detail

Recent advances in pharmacophore modeling and its application to anti-influenza drug discovery.
MedLine Citation:
PMID:  23373617     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: The emergence of the highly pathogenic avian influenza (HPAI) H5N1 virus and the recent global circulation of H1N1 swine-origin influenza virus in 2009 have highlighted the need for new anti-influenza therapies. This has been made all the more important with the emergence of antiviral-resistant strains. Recent progress in achieving three-dimensional (3D) crystal structures of influenza viral proteins and efficient tools available for pharmacophore-based virtual screening are aiding us in the discovery and design of new antiviral compounds.
AREAS COVERED: This review discusses pharmacophore modeling as a potential cost-effective and time-saving technology for new drug discovery as an alternative to high-throughput screening. Based on this technical platform, the authors discuss current progress and future prospects for developing novel influenza antivirals against pre-existing or emerging novel targets.
EXPERT OPINION: Although it might be at an infant stage of development, the availability of the 3D crystal structures of influenza viral proteins is expected to accelerate the application of structure-based drug design (SBDD) and pharmacophore modeling. Furthermore, the neuraminidase inhibitor, one of the most successful examples of a SBDD, still receives great attention because of its superb antiviral activities and the resistance of influenza strains to oseltamivir. However, despite much success, pharmacophore-based virtual screening exhibits limited predictive power in hit identification. Further improvements in pharmacophore detection algorithms, proper combinations of in silico methods as well as judicious choosing of compounds are expected to improve the hit rate. With the help of these technologies, the discovery of anti-influenza agents will be accelerated.
Woo-Jin Shin; Baik Lin Seong
Related Documents :
23802437 - Antiherpetic efficacy of aqueous extracts of the cyanobacterium arthrospira fusiformis ...
24695077 - Increased levels of plasma galectin-9 in patients with influenza virus infection.
23725047 - Chikungunya virus with e1-a226v mutation causing two outbreaks in 2010, guangdong, china.
23169977 - Results from the first 30 months of national sentinel surveillance for influenza in tan...
25381057 - Rna transcripts of full-length cdna clones of rabbit hepatitis e virus are infectious i...
501797 - Carbohydrates of influenza virus. iii. nature of oligosaccharide-protein linkage in vir...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2013-02-04
Journal Detail:
Title:  Expert opinion on drug discovery     Volume:  8     ISSN:  1746-045X     ISO Abbreviation:  Expert Opin Drug Discov     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-03-20     Completed Date:  2013-08-13     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101295755     Medline TA:  Expert Opin Drug Discov     Country:  England    
Other Details:
Languages:  eng     Pagination:  411-26     Citation Subset:  IM    
College of Life Science and Biotechnology, Department of Biotechnology, Seoul 120-749, South Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiviral Agents / pharmacology*
Drug Design*
Influenza, Human / drug therapy*
Models, Theoretical
Structure-Activity Relationship
Reg. No./Substance:
0/Antiviral Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Elucidation of haem-binding sites in the actinobacterial protein HbpS.
Next Document:  In Vivo Assessment of Absorbable Knotless Barbed Suture for Single Layer Gastrotomy and Enterotomy C...